Health technology presents a highly disruptive challenge to the status quo across the entire healthcare ecoystem. But the sector has high inertia to technological change rooted in evidence based regulatory pathways; complex reimbursement systems and entrenched clinical practices, which add an additional dimension to corporate strategy.
Elixir helps companies to navigate the rapidly changing landscape; to identify defendable corporate strategies and identify and deliver value-creating deals.
The Biopharma industry is built on the ever-shifting foundations of clinical innovation. But the industry also faces many additional macro challenges over the coming years including ever-more-complex regulatory requirements, tightening reimbursement and the inclusion of new health technologies.
Elixir helps companies to unpick the complexities of the clinical landscape and to identify and deliver those opportunities and strategies which might provide access to finite capital resources and/or lead to commercial success.
The distribution of medical equipment and devices is highly nuanced with different territories, healthcare systems and products demanding bespoke solutions resulting in a surprisingly rich array of business models and strategies. In an industry where the purchasing power of the buyers and suppliers is maximal, strategy has a disproportionate effect on returns.
Elixir helps companies to identify strategic opportunities to build competitive strength and which enhance both the top and bottom line.
Outsourced clinical research continues to undergo significant technological (see Health Technology) and regulatory change as customers struggle to combat the inexorable increase in the cost of clinical development and declining returns on investment (see BioPharma). Customer demands for rapid/successful delivery, specialist expertise and lower costs disadvantage smaller players.
Elixir has experience of building successful CRO strategies and identifying and delivering opportunities across the highly fragmented CRO landscape.
The sector has been commoditised by low cost Asian entrants, driving a move towards higher margin specialised products/solutions with dedicated consumables (not reagents) and clinical applications. Customers also demand data-centric and cloud-connected, "smart lab" solutions which are highly ecosystem-centric: Companies face challenges claiming and defending market position against large, integrated competitors.
Elixir has helped LifeSciences tools companies to better understand the competitive landscape and to deliver transactions with meaningful strategic impact.